Solara Active Pharma Sciences Ltd.

As of June 30, 2026, Solara Active Pharma Sciences Ltd. carries a market capitalization of 27.67B, placing it among publicly traded companies globally. Its enterprise value stands at 27.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Solara Active Pharma Sciences Ltd.'s next confirmed earnings release is scheduled for February 11, 2027.

As of June 30, 2026, Solara Active Pharma Sciences Ltd. has 48.06M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Solara Active Pharma Sciences Ltd. trades at an EV/EBITDA multiple of 14.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 27.67B versus a market cap of 27.67B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.75M in revenue per employee across its workforce of 3,016.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Solara Active Pharma Sciences Ltd.'s stock has gained approximately 3.16% over the past 52 weeks. The 50-day moving average sits at 656.75, while the 200-day moving average is 552.78.

Over the twelve months ended June 30, 2026, Solara Active Pharma Sciences Ltd. generated 14.31B in revenue and converted that into -16.20M in net income, yielding earnings per share of -0.37. EBITDA reached 1.86B, while operating income came in at 888.90M.

Over the twelve months ended June 30, 2026, Solara Active Pharma Sciences Ltd. posted a gross margin of 48.69, reflecting its pricing power and cost economics. The operating margin of 6.21 and net profit margin of -0.11 provide insight into operational efficiency.

Solara Active Pharma Sciences Ltd.'s most recent stock split took place on May 15, 2024 with a 247:268 split ratio.